| Item 1. | |
| (a) | Name of issuer:
OnKure Therapeutics Inc. |
| (b) | Address of issuer's principal executive offices:
6707 Winchester Circle, Suite 400 Boulder, CO 80301 |
| Item 2. | |
| (a) | Name of person filing:
Cantor Fitzgerald & Co., Cantor Fitzgerald Securities, Cantor Fitzgerald, L.P., CF Group Management and Inc. (collectively, the "Reporting Persons"). |
| (b) | Address or principal business office or, if none, residence:
110 East 59th Street
New York, New York 10022 |
| (c) | Citizenship:
Cantor Fitzgerald & Co. is a general partnership formed in New York, Cantor Fitzgerald Securities is a general partnership formed in New York, Cantor Fitzgerald, L.P. is a Delaware limited partnership, CF Group Management, Inc. is a New York corporation. |
| (d) | Title of class of securities:
Class A Common Stock, par value $0.0001 per share |
| (e) | CUSIP No.:
68277Q105 |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) |  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
|
| | |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference.
As of June 30, 2025, the Reporting Persons may be deemed to beneficially own an aggregate of 669,539 shares of Class A Common Stock, par value $0.0001 per share ("Common Stock") of OnKure Therapeutics, Inc. (the "Issuer"), representing 5.2% of the Issuer's outstanding Common Stock.
The percentage of the Common Stock held by the Reporting Persons is based on 12,823,872 shares of Common Stock outstanding as of May 5, 2025 as reported in the Issuer's Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Securities and Exchange Commission on May 6, 2025.
Cantor Fitzgerald & Co. ("CF&Co.") is the record holder of certain of the securities reported herein.
Cantor Fitzgerald Securities ("CFS") controls the managing general partner of CF&CO. Cantor Fitzgerald, L.P. ("CFLP") indirectly controls each of CFS and CF&CO. CFLP is controlled by CF Group Management, Inc. ("CFGM"), its managing general partner. As such, each of CFS, CFLP and CFGM may be deemed to have beneficial ownership of the securities directly held by CF&CO. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly. On May 16, 2025, Howard W. Lutnick, in his capacity as trustee of a trust, entered into agreements to sell to trusts controlled by Brandon G. Lutnick all of the voting shares of CFGM. Following the closing of the transactions contemplated by such agreements, Brandon G. Lutnick will be deemed to have voting or dispositive power over the Common Stock held by CFGM. The closings of the transactions contemplated by such agreements are subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals. The transactions described herein follow Howard W. Lutnick's agreement to divest his interests in CFLP to comply with U.S. government ethics rules in connection with his appointment as the U.S. Secretary of Commerce. |
| (b) | Percent of class:
See response to Item 11 on each cover page. |
| (c) | Number of shares as to which the person has:
|
| | (i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
|
| | (ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
|
| | (iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
|
| | (iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
|
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
| |
Not Applicable
|
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| |
Not Applicable
|
| Item 8. | Identification and Classification of Members of the Group. |
| |
Not Applicable
|
| Item 9. | Notice of Dissolution of Group. |
| |
Not Applicable
|
Rule 13d-1(c)